EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kennedy, S. P.
Right arrow Articles by Bormann, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kennedy, S. P.
Right arrow Articles by Bormann, B. J.
Experimental Biology and Medicine 231:1690-1694 (2006)
© 2006 Society for Experimental Biology and Medicine

SYMPOSIA

Effective Partnering of Academic and Physician Scientists with the Pharmaceutical Drug Development Industry

Scott P. Kennedy*,1 and B. J. Bormann{dagger}

* Drug Safety Research and Development, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut 06340; and {dagger} Strategic Alliances, Pfizer Global Research and Development, Pfizer Inc., New London, Connecticut 06320

To whom requests for reprints should be addressed at 1 Drug Safety Research and Development, Pfizer Global Research and Development, Pfizer Inc., Eastern Point Road, Groton, CT 06340. E-mail: Scott.P.Kennedy{at}Pfizer.com

This manuscript briefly addresses the drug discovery and development process. It is a long road from the formulation of a good discovery idea to the acceptance of a new drug in the marketplace, and there are many challenges faced along the way to the patient. Collaborations and partnerships are an important part of this process. There are a variety of partnering opportunities, ranging from the discovery of novel technologies and drug targets to lead discovery, compound gifts, and external sourcing. These partnerships help increase confidence and improve decision making on issues of safety and efficacy preclinically, which can reduce attrition and expedite the provision of new quality drugs to patients more quickly and at lower costs. Collaborations involve addressing multiple issues that include infrastructure, safety, regulatory matters, intellectual property, technical and personnel considerations, source document capture and data analysis issues, and legal and strategic alliances. A number of success factors are identified as important for quality collaborations in the drug development process.

Key Words: academia • drug development, industry • partnering • physician scientist • safety






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Experimental Biology and Medicine.